Global Dry Eye Syndrome Drugs 麻豆原创 Research Report 2025

You are here: 麻豆原创 Catalog Pharma & Healthcare Healthcare

Global Dry Eye Syndrome Drugs 麻豆原创 Research Report 2025

麻豆原创 Research Report Summary

Global Dry Eye Syndrome Drugs 麻豆原创 Research Report 2025 report is published on May 28, 2025 and has 98 pages in it. This market research report provides information about Healthcare, Pharma & Healthcare industry. It covers Global market data and forecasts. It is priced starting at USD 2,900.00 for Single User License (PDF) which allows one person to use this report.

Please read the description and table of contents of this research report given below to check whether it meets your research requirements. If not, then please do not hesitate to contact us using "Report Enquiry" form given below. We can customize this research report or suggest a new fully customized market research report to meet your research goals and data requirements.

Global Dry Eye Syndrome Drugs 麻豆原创 Research Report 2025

Printer version

Send by email

Publication ID:听

PB505250452

Publication Date:听

May 28, 2025

笔补驳别蝉:听

98

笔耻产濒颈蝉丑别谤:听

MRRPB5

颁辞耻苍迟谤颈别蝉:听

Global

USD 2,900.00

Pay By Invoice

If you wish to purchase this report using bank/wire transfer against an invoice, please fill your details using request invoice form given below.

Globally Trusted Brand

We help executives from firms听to Start-ups听with their market research needs thus听we can help you too.听

Secure Checkout

You can shop confidently as your online payments are processed using PCI DSS compliant secure payment gateways on our website.

Frequently Asked Questions

If you have any pre-sales听questions related to this report please let us know using the "Report Enquiry" form below. This will help us provide you听with answers听so that you can purchase with confidence. If you wish to read about frequently asked questions by our customers please visit our .

Tabs

Description

The global market for Dry Eye Syndrome Drugs was valued at US$ 5876 million in the year 2024 and is projected to reach a revised size of US$ 7959 million by 2031, growing at a CAGR of 4.5% during the forecast period.
Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. The symptoms can range from mild and occasional to severe and continuous. Scarring of the cornea may occur in some cases without treatment. In this report, we mainly study the drugs and eye drops for dry eye.
The Dry Eye Syndrome market is driven by the rising prevalence of dry eye conditions globally, fueled by aging populations, increased screen time, and lifestyle-related factors. The widespread use of digital devices has significantly contributed to eye strain and reduced blink rates, leading to a surge in dry eye cases, especially among younger demographics. Additionally, growing awareness of ocular health and improved diagnosis through advanced diagnostic tools have increased patient identification and treatment rates. The introduction of innovative therapies, including anti-inflammatory eye drops, tear-stimulating drugs, and device-based treatments, is also expanding the market landscape.
Despite growing demand, the Dry Eye Syndrome market faces several challenges, including underdiagnosis, variable symptoms, and limited long-term treatment efficacy. Many patients remain undiagnosed due to the overlap of symptoms with other ocular conditions and the subjective nature of the disease. Current treatments often offer only temporary relief rather than a cure, leading to poor adherence and patient dissatisfaction. Moreover, the development of new therapies is hindered by the complex pathophysiology of the condition, which involves both aqueous and evaporative components. Addressing these challenges requires improved diagnostic criteria, personalized treatment approaches, and increased investment in research and clinical trials.
This report aims to provide a comprehensive presentation of the global market for Dry Eye Syndrome Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dry Eye Syndrome Drugs.
The Dry Eye Syndrome Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Dry Eye Syndrome Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dry Eye Syndrome Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
AbbVie
Alcon
Novartis
Santen Pharma
Johnson & Johnson
Bausch & Lomb
Thea pharmaceuticals
URSAPHARM
SIMILASAN
Akorn
United Laboratories
Sun Pharmaceutical
Jianfeng Group
OmniVision Pharma
Rohto
Prestige Consumer Healthcare
LION
Kenvue (VISINE)
Segment by Type
Artificial Tears
Anti-inflammatory Drugs
Other
Segment by Application
Hospitals
Clinics
麻豆原创care
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dry Eye Syndrome Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Dry Eye Syndrome Drugs 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Artificial Tears
1.2.3 Anti-inflammatory Drugs
1.2.4 Other
1.3 麻豆原创 by Application
1.3.1 Global Dry Eye Syndrome Drugs 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 麻豆原创care
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Dry Eye Syndrome Drugs 麻豆原创 Perspective (2020-2031)
2.2 Global Dry Eye Syndrome Drugs Growth Trends by Region
2.2.1 Global Dry Eye Syndrome Drugs 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Dry Eye Syndrome Drugs Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Dry Eye Syndrome Drugs Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Dry Eye Syndrome Drugs 麻豆原创 Dynamics
2.3.1 Dry Eye Syndrome Drugs Industry Trends
2.3.2 Dry Eye Syndrome Drugs 麻豆原创 Drivers
2.3.3 Dry Eye Syndrome Drugs 麻豆原创 Challenges
2.3.4 Dry Eye Syndrome Drugs 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Dry Eye Syndrome Drugs Players by Revenue
3.1.1 Global Top Dry Eye Syndrome Drugs Players by Revenue (2020-2025)
3.1.2 Global Dry Eye Syndrome Drugs Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Top Dry Eye Syndrome Drugs Players by Company Type and 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Dry Eye Syndrome Drugs Revenue
3.4 Global Dry Eye Syndrome Drugs 麻豆原创 Concentration Ratio
3.4.1 Global Dry Eye Syndrome Drugs 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Dry Eye Syndrome Drugs Revenue in 2024
3.5 Global Key Players of Dry Eye Syndrome Drugs Head office and Area Served
3.6 Global Key Players of Dry Eye Syndrome Drugs, Product and Application
3.7 Global Key Players of Dry Eye Syndrome Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Dry Eye Syndrome Drugs Breakdown Data by Type
4.1 Global Dry Eye Syndrome Drugs Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Dry Eye Syndrome Drugs Forecasted 麻豆原创 Size by Type (2026-2031)
5 Dry Eye Syndrome Drugs Breakdown Data by Application
5.1 Global Dry Eye Syndrome Drugs Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Dry Eye Syndrome Drugs Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Dry Eye Syndrome Drugs 麻豆原创 Size (2020-2031)
6.2 North America Dry Eye Syndrome Drugs 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Dry Eye Syndrome Drugs 麻豆原创 Size by Country (2020-2025)
6.4 North America Dry Eye Syndrome Drugs 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Dry Eye Syndrome Drugs 麻豆原创 Size (2020-2031)
7.2 Europe Dry Eye Syndrome Drugs 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Dry Eye Syndrome Drugs 麻豆原创 Size by Country (2020-2025)
7.4 Europe Dry Eye Syndrome Drugs 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Dry Eye Syndrome Drugs 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Dry Eye Syndrome Drugs 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Dry Eye Syndrome Drugs 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Dry Eye Syndrome Drugs 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Dry Eye Syndrome Drugs 麻豆原创 Size (2020-2031)
9.2 Latin America Dry Eye Syndrome Drugs 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Dry Eye Syndrome Drugs 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Dry Eye Syndrome Drugs 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Dry Eye Syndrome Drugs 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Dry Eye Syndrome Drugs 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Dry Eye Syndrome Drugs 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Dry Eye Syndrome Drugs 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Dry Eye Syndrome Drugs Introduction
11.1.4 AbbVie Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.1.5 AbbVie Recent Development
11.2 Alcon
11.2.1 Alcon Company Details
11.2.2 Alcon Business Overview
11.2.3 Alcon Dry Eye Syndrome Drugs Introduction
11.2.4 Alcon Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.2.5 Alcon Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Dry Eye Syndrome Drugs Introduction
11.3.4 Novartis Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.3.5 Novartis Recent Development
11.4 Santen Pharma
11.4.1 Santen Pharma Company Details
11.4.2 Santen Pharma Business Overview
11.4.3 Santen Pharma Dry Eye Syndrome Drugs Introduction
11.4.4 Santen Pharma Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.4.5 Santen Pharma Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Dry Eye Syndrome Drugs Introduction
11.5.4 Johnson & Johnson Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.5.5 Johnson & Johnson Recent Development
11.6 Bausch & Lomb
11.6.1 Bausch & Lomb Company Details
11.6.2 Bausch & Lomb Business Overview
11.6.3 Bausch & Lomb Dry Eye Syndrome Drugs Introduction
11.6.4 Bausch & Lomb Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.6.5 Bausch & Lomb Recent Development
11.7 Thea pharmaceuticals
11.7.1 Thea pharmaceuticals Company Details
11.7.2 Thea pharmaceuticals Business Overview
11.7.3 Thea pharmaceuticals Dry Eye Syndrome Drugs Introduction
11.7.4 Thea pharmaceuticals Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.7.5 Thea pharmaceuticals Recent Development
11.8 URSAPHARM
11.8.1 URSAPHARM Company Details
11.8.2 URSAPHARM Business Overview
11.8.3 URSAPHARM Dry Eye Syndrome Drugs Introduction
11.8.4 URSAPHARM Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.8.5 URSAPHARM Recent Development
11.9 SIMILASAN
11.9.1 SIMILASAN Company Details
11.9.2 SIMILASAN Business Overview
11.9.3 SIMILASAN Dry Eye Syndrome Drugs Introduction
11.9.4 SIMILASAN Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.9.5 SIMILASAN Recent Development
11.10 Akorn
11.10.1 Akorn Company Details
11.10.2 Akorn Business Overview
11.10.3 Akorn Dry Eye Syndrome Drugs Introduction
11.10.4 Akorn Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.10.5 Akorn Recent Development
11.11 United Laboratories
11.11.1 United Laboratories Company Details
11.11.2 United Laboratories Business Overview
11.11.3 United Laboratories Dry Eye Syndrome Drugs Introduction
11.11.4 United Laboratories Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.11.5 United Laboratories Recent Development
11.12 Sun Pharmaceutical
11.12.1 Sun Pharmaceutical Company Details
11.12.2 Sun Pharmaceutical Business Overview
11.12.3 Sun Pharmaceutical Dry Eye Syndrome Drugs Introduction
11.12.4 Sun Pharmaceutical Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.12.5 Sun Pharmaceutical Recent Development
11.13 Jianfeng Group
11.13.1 Jianfeng Group Company Details
11.13.2 Jianfeng Group Business Overview
11.13.3 Jianfeng Group Dry Eye Syndrome Drugs Introduction
11.13.4 Jianfeng Group Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.13.5 Jianfeng Group Recent Development
11.14 OmniVision Pharma
11.14.1 OmniVision Pharma Company Details
11.14.2 OmniVision Pharma Business Overview
11.14.3 OmniVision Pharma Dry Eye Syndrome Drugs Introduction
11.14.4 OmniVision Pharma Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.14.5 OmniVision Pharma Recent Development
11.15 Rohto
11.15.1 Rohto Company Details
11.15.2 Rohto Business Overview
11.15.3 Rohto Dry Eye Syndrome Drugs Introduction
11.15.4 Rohto Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.15.5 Rohto Recent Development
11.16 Prestige Consumer Healthcare
11.16.1 Prestige Consumer Healthcare Company Details
11.16.2 Prestige Consumer Healthcare Business Overview
11.16.3 Prestige Consumer Healthcare Dry Eye Syndrome Drugs Introduction
11.16.4 Prestige Consumer Healthcare Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.16.5 Prestige Consumer Healthcare Recent Development
11.17 LION
11.17.1 LION Company Details
11.17.2 LION Business Overview
11.17.3 LION Dry Eye Syndrome Drugs Introduction
11.17.4 LION Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.17.5 LION Recent Development
11.18 Kenvue (VISINE)
11.18.1 Kenvue (VISINE) Company Details
11.18.2 Kenvue (VISINE) Business Overview
11.18.3 Kenvue (VISINE) Dry Eye Syndrome Drugs Introduction
11.18.4 Kenvue (VISINE) Revenue in Dry Eye Syndrome Drugs Business (2020-2025)
11.18.5 Kenvue (VISINE) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Tables and Figures

List of Tables
Table 1. Global Dry Eye Syndrome Drugs 麻豆原创 Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Artificial Tears
Table 3. Key Players of Anti-inflammatory Drugs
Table 4. Key Players of Other
Table 5. Global Dry Eye Syndrome Drugs 麻豆原创 Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Dry Eye Syndrome Drugs 麻豆原创 Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Dry Eye Syndrome Drugs 麻豆原创 Size by Region (2020-2025) & (US$ Million)
Table 8. Global Dry Eye Syndrome Drugs 麻豆原创 Share by Region (2020-2025)
Table 9. Global Dry Eye Syndrome Drugs Forecasted 麻豆原创 Size by Region (2026-2031) & (US$ Million)
Table 10. Global Dry Eye Syndrome Drugs 麻豆原创 Share by Region (2026-2031)
Table 11. Dry Eye Syndrome Drugs 麻豆原创 Trends
Table 12. Dry Eye Syndrome Drugs 麻豆原创 Drivers
Table 13. Dry Eye Syndrome Drugs 麻豆原创 Challenges
Table 14. Dry Eye Syndrome Drugs 麻豆原创 Restraints
Table 15. Global Dry Eye Syndrome Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Dry Eye Syndrome Drugs 麻豆原创 Share by Players (2020-2025)
Table 17. Global Top Dry Eye Syndrome Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dry Eye Syndrome Drugs as of 2024)
Table 18. Ranking of Global Top Dry Eye Syndrome Drugs Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players 麻豆原创 Share by Dry Eye Syndrome Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Dry Eye Syndrome Drugs, Headquarters and Area Served
Table 21. Global Key Players of Dry Eye Syndrome Drugs, Product and Application
Table 22. Global Key Players of Dry Eye Syndrome Drugs, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Dry Eye Syndrome Drugs 麻豆原创 Size by Type (2020-2025) & (US$ Million)
Table 25. Global Dry Eye Syndrome Drugs Revenue 麻豆原创 Share by Type (2020-2025)
Table 26. Global Dry Eye Syndrome Drugs Forecasted 麻豆原创 Size by Type (2026-2031) & (US$ Million)
Table 27. Global Dry Eye Syndrome Drugs Revenue 麻豆原创 Share by Type (2026-2031)
Table 28. Global Dry Eye Syndrome Drugs 麻豆原创 Size by Application (2020-2025) & (US$ Million)
Table 29. Global Dry Eye Syndrome Drugs Revenue 麻豆原创 Share by Application (2020-2025)
Table 30. Global Dry Eye Syndrome Drugs Forecasted 麻豆原创 Size by Application (2026-2031) & (US$ Million)
Table 31. Global Dry Eye Syndrome Drugs Revenue 麻豆原创 Share by Application (2026-2031)
Table 32. North America Dry Eye Syndrome Drugs 麻豆原创 Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Dry Eye Syndrome Drugs 麻豆原创 Size by Country (2020-2025) & (US$ Million)
Table 34. North America Dry Eye Syndrome Drugs 麻豆原创 Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Dry Eye Syndrome Drugs 麻豆原创 Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Dry Eye Syndrome Drugs 麻豆原创 Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Dry Eye Syndrome Drugs 麻豆原创 Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Dry Eye Syndrome Drugs 麻豆原创 Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Dry Eye Syndrome Drugs 麻豆原创 Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Dry Eye Syndrome Drugs 麻豆原创 Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Dry Eye Syndrome Drugs 麻豆原创 Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Dry Eye Syndrome Drugs 麻豆原创 Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Dry Eye Syndrome Drugs 麻豆原创 Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Dry Eye Syndrome Drugs 麻豆原创 Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Dry Eye Syndrome Drugs 麻豆原创 Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Dry Eye Syndrome Drugs 麻豆原创 Size by Country (2026-2031) & (US$ Million)
Table 47. AbbVie Company Details
Table 48. AbbVie Business Overview
Table 49. AbbVie Dry Eye Syndrome Drugs Product
Table 50. AbbVie Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 51. AbbVie Recent Development
Table 52. Alcon Company Details
Table 53. Alcon Business Overview
Table 54. Alcon Dry Eye Syndrome Drugs Product
Table 55. Alcon Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 56. Alcon Recent Development
Table 57. Novartis Company Details
Table 58. Novartis Business Overview
Table 59. Novartis Dry Eye Syndrome Drugs Product
Table 60. Novartis Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 61. Novartis Recent Development
Table 62. Santen Pharma Company Details
Table 63. Santen Pharma Business Overview
Table 64. Santen Pharma Dry Eye Syndrome Drugs Product
Table 65. Santen Pharma Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 66. Santen Pharma Recent Development
Table 67. Johnson & Johnson Company Details
Table 68. Johnson & Johnson Business Overview
Table 69. Johnson & Johnson Dry Eye Syndrome Drugs Product
Table 70. Johnson & Johnson Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 71. Johnson & Johnson Recent Development
Table 72. Bausch & Lomb Company Details
Table 73. Bausch & Lomb Business Overview
Table 74. Bausch & Lomb Dry Eye Syndrome Drugs Product
Table 75. Bausch & Lomb Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 76. Bausch & Lomb Recent Development
Table 77. Thea pharmaceuticals Company Details
Table 78. Thea pharmaceuticals Business Overview
Table 79. Thea pharmaceuticals Dry Eye Syndrome Drugs Product
Table 80. Thea pharmaceuticals Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 81. Thea pharmaceuticals Recent Development
Table 82. URSAPHARM Company Details
Table 83. URSAPHARM Business Overview
Table 84. URSAPHARM Dry Eye Syndrome Drugs Product
Table 85. URSAPHARM Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 86. URSAPHARM Recent Development
Table 87. SIMILASAN Company Details
Table 88. SIMILASAN Business Overview
Table 89. SIMILASAN Dry Eye Syndrome Drugs Product
Table 90. SIMILASAN Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 91. SIMILASAN Recent Development
Table 92. Akorn Company Details
Table 93. Akorn Business Overview
Table 94. Akorn Dry Eye Syndrome Drugs Product
Table 95. Akorn Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 96. Akorn Recent Development
Table 97. United Laboratories Company Details
Table 98. United Laboratories Business Overview
Table 99. United Laboratories Dry Eye Syndrome Drugs Product
Table 100. United Laboratories Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 101. United Laboratories Recent Development
Table 102. Sun Pharmaceutical Company Details
Table 103. Sun Pharmaceutical Business Overview
Table 104. Sun Pharmaceutical Dry Eye Syndrome Drugs Product
Table 105. Sun Pharmaceutical Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 106. Sun Pharmaceutical Recent Development
Table 107. Jianfeng Group Company Details
Table 108. Jianfeng Group Business Overview
Table 109. Jianfeng Group Dry Eye Syndrome Drugs Product
Table 110. Jianfeng Group Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 111. Jianfeng Group Recent Development
Table 112. OmniVision Pharma Company Details
Table 113. OmniVision Pharma Business Overview
Table 114. OmniVision Pharma Dry Eye Syndrome Drugs Product
Table 115. OmniVision Pharma Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 116. OmniVision Pharma Recent Development
Table 117. Rohto Company Details
Table 118. Rohto Business Overview
Table 119. Rohto Dry Eye Syndrome Drugs Product
Table 120. Rohto Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 121. Rohto Recent Development
Table 122. Prestige Consumer Healthcare Company Details
Table 123. Prestige Consumer Healthcare Business Overview
Table 124. Prestige Consumer Healthcare Dry Eye Syndrome Drugs Product
Table 125. Prestige Consumer Healthcare Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 126. Prestige Consumer Healthcare Recent Development
Table 127. LION Company Details
Table 128. LION Business Overview
Table 129. LION Dry Eye Syndrome Drugs Product
Table 130. LION Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 131. LION Recent Development
Table 132. Kenvue (VISINE) Company Details
Table 133. Kenvue (VISINE) Business Overview
Table 134. Kenvue (VISINE) Dry Eye Syndrome Drugs Product
Table 135. Kenvue (VISINE) Revenue in Dry Eye Syndrome Drugs Business (2020-2025) & (US$ Million)
Table 136. Kenvue (VISINE) Recent Development
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
Table 140. Authors List of This Report

List of Figures
Figure 1. Dry Eye Syndrome Drugs Picture
Figure 2. Global Dry Eye Syndrome Drugs 麻豆原创 Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Dry Eye Syndrome Drugs 麻豆原创 Share by Type: 2024 VS 2031
Figure 4. Artificial Tears Features
Figure 5. Anti-inflammatory Drugs Features
Figure 6. Other Features
Figure 7. Global Dry Eye Syndrome Drugs 麻豆原创 Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Dry Eye Syndrome Drugs 麻豆原创 Share by Application: 2024 VS 2031
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. 麻豆原创care Case Studies
Figure 12. Others Case Studies
Figure 13. Dry Eye Syndrome Drugs Report Years Considered
Figure 14. Global Dry Eye Syndrome Drugs 麻豆原创 Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Dry Eye Syndrome Drugs 麻豆原创 Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Dry Eye Syndrome Drugs 麻豆原创 Share by Region: 2024 VS 2031
Figure 17. Global Dry Eye Syndrome Drugs 麻豆原创 Share by Players in 2024
Figure 18. Global Dry Eye Syndrome Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 19. The Top 10 and 5 Players 麻豆原创 Share by Dry Eye Syndrome Drugs Revenue in 2024
Figure 20. North America Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Dry Eye Syndrome Drugs 麻豆原创 Share by Country (2020-2031)
Figure 22. United States Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Dry Eye Syndrome Drugs 麻豆原创 Share by Country (2020-2031)
Figure 26. Germany Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Dry Eye Syndrome Drugs 麻豆原创 Share by Region (2020-2031)
Figure 34. China Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Dry Eye Syndrome Drugs 麻豆原创 Share by Country (2020-2031)
Figure 42. Mexico Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Dry Eye Syndrome Drugs 麻豆原创 Share by Country (2020-2031)
Figure 46. Turkey Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Dry Eye Syndrome Drugs 麻豆原创 Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. AbbVie Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 50. Alcon Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 51. Novartis Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 52. Santen Pharma Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 53. Johnson & Johnson Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 54. Bausch & Lomb Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 55. Thea pharmaceuticals Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 56. URSAPHARM Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 57. SIMILASAN Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 58. Akorn Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 59. United Laboratories Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 60. Sun Pharmaceutical Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 61. Jianfeng Group Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 62. OmniVision Pharma Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 63. Rohto Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 64. Prestige Consumer Healthcare Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 65. LION Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 66. Kenvue (VISINE) Revenue Growth Rate in Dry Eye Syndrome Drugs Business (2020-2025)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

Companies Covered

AbbVie
Alcon
Novartis
Santen Pharma
Johnson & Johnson
Bausch & Lomb
Thea pharmaceuticals
URSAPHARM
SIMILASAN
Akorn
United Laboratories
Sun Pharmaceutical
Jianfeng Group
OmniVision Pharma
Rohto
Prestige Consumer Healthcare
LION
Kenvue (VISINE)

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Enquiry / Request Invoice

Report Inquiry

Do you have more questions related to this market research report after going through the description and table of contents?

We are here to help. Please use the form given below to let us know your questions related to this report.

Kindly use your official email address and contact number to ensure speedy response.

First Name *

Last Name *

Company *

Email Address *

Phone (Including International Code) *

Report Title *

Do you need invoice for purchasing this report? *

Address 1

Address 2

City/Town

Postal/Zip Code

Country

License Type

Your Inquiry *

CAPTCHA

This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Healthcare

Pharma & Healthcare

*Please note that the report cover image shown above is for representation purpose only. Actual report cover may vary.

听

Related 麻豆原创 Research Reports

Publication	Price
Global Agrigenomics 麻豆原创 2025 by Company, Regions, Type and Application, Forecast to 2031 The global Agrigenomics market size was valued at US$ 5643 million in 2024 and is forecast to a readjusted size of USD 8587 million by 2031 with a CAGR of 6.2% during review period. Agrigenomics is product and scientific services in genomics field for agriculture and livestock. Include DNA extraction and purification, DNA/RNA sequencing, Genotyping, Gene expression profiling, Marker-assisted selection, GMO/Trait purity and other technology. Thermo Fisher Scientific, Illumina, Agilent Technologies, Eurofins and Zoetis are the leaders of the Agrigenomics industry, which take about 40% market share. North America is the major region of the global market, which takes about 50% market share. This report is a detailed and comprehensive analysis for global Agrigenomics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition...Read more	USD 3,480.00
Global Oxyclozanide 麻豆原创 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031 The global Oxyclozanide market size was valued at US$ 34.8 million in 2024 and is forecast to a readjusted size of USD 65.8 million by 2031 with a CAGR of 9.7% during review period. Oxyclozanide is a salicylanilide anthelmintic. It is used in the treatment and control of fascioliasis in ruminants mainly domestic animals such as cattle, sheep, and goats. It mainly acts by uncoupling of oxidative phosphorylation in flukes. Global Oxyclozanide main players are Siflon Drug, Yabang, Gharda, ASCENT PHARMA, Aarambh Life Science, etc. Top five companies hold a share above 50%. Africa is the largest market, with a share about 30%. This report is a detailed and comprehensive analysis for global Oxyclozanide market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that...Read more	USD 3,480.00
Global Artificial Tears 麻豆原创 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031 The global Artificial Tears market size was valued at US$ 3541 million in 2024 and is forecast to a readjusted size of USD 6189 million by 2031 with a CAGR of 8.4% during review period. Artificial tears are lubricant eye drops used to treat the dryness and irritation associated with deficient tear production in keratoconjunctivitis sicca (dry eyes). They are also used to moisten contact lenses and in eye examinations. The industry"s leading producers are Allergan, Alcon and Bausch & Lomb, with revenues of 23.40%, 27.67% and 8.98%, respectively, in 2019. This report is a detailed and comprehensive analysis for global Artificial Tears market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets....Read more	USD 3,480.00
Global Transdermal Patch 麻豆原创 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031 The global Transdermal Patch market size was valued at US$ 7498 million in 2024 and is forecast to a readjusted size of USD 9524 million by 2031 with a CAGR of 3.5% during review period. Transdermal Patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream.Transdermal Patches include fentanyl transdermal patch, nicotine transdermal patch, buprenorphine transdermal patch, clonidine transdermal patch, oxybutynin transdermal patch, estradiol transdermal patch, nitroglycerin transdermal patch and many others. Transdermal Patches are mainly classified into the following types: Methyl Salicylate-based Patches, Rivastigmine Patches, Fentanyl Patches, Lidocaine Patches, Diclofenac Patches, Nicotine Patches and others. Methyl Salicylate-based segment accounted for the larger part of the revenue market, with 18%, followed by Lidocaine Patches, with 15%. Transdermal Patches can delivery...Read more	USD 3,480.00
Global Rabies Vaccine 麻豆原创 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031 The global Rabies Vaccine market size was valued at US$ 1036 million in 2024 and is forecast to a readjusted size of USD 1350 million by 2031 with a CAGR of 3.9% during review period. Rabies vaccine is an active immunizing agent used to prevent infection caused by the rabies virus. The vaccine works by causing your body to produce its own protection (antibodies) against the rabies virus. Global Rabies Vaccine key players include Chengda, Changsheng, Prcmise, VACN, etc. Global top four manufacturers hold a share about 70%. China is the largest market, with a share about 85%, followed by Europe, and North America, both have a share over 10 percent. In terms of product, Vero Cell Rabies Vaccine is the largest segment, with a share over 75%. And in terms of application, the largest application is Post-exposure Prophylaxis, followed by Pre-exposure Prophylaxis. This report is a detailed and comprehensive analysis for global Rabies Vaccine market. Both...Read more	USD 3,480.00

Clients Who Trust Us

Need tailor made market research solution? We can help you with that too.

Contact Us

About Us

At 麻豆原创 we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer鈥檚 needs, be it custom research or syndicated research reports.

Contact Us

麻豆原创 Research Reports, Inc
16192 Coastal Hwy
Lewes, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

Latest Blog Posts

Stay Connected

Disclaimer: 麻豆原创 has no affiliation to, and is not associated with any other website(s) or organization(s). We offer syndicated research reports (like country analysis, SWOT analysis, competitive intelligence, industry reports, company reports and market analysis & trends reports) and custom market research from our website 麻豆原创ResearchReports.com only.

If you are looking for a market research solution for your research requirements, please begin your search using the search box on top of this page or use our chat system to speak to our market research consultants or directly write to us.

麻豆原创